Massive new registry aims to unlock secrets of deadly heart shock
NCT ID NCT07643610
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This registry will collect health information from 8,000 patients with cardiogenic shock, a life-threatening condition where the heart suddenly can't pump enough blood. Researchers will track what treatments patients receive and how they fare, including survival rates in the hospital and at 30 and 90 days. No new drugs or devices are being tested; the goal is to learn from real-world care to improve future treatment guidelines.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this registry could help doctors better understand which treatments work best for cardiogenic shock, potentially improving survival rates.
- What could go wrong
- This is an observational registry, not a clinical trial testing a new therapy. It collects existing data and cannot prove cause and effect. Results may take years to influence practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 8,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Oct 2035
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients who are treated at the University Hospital Basel and are diagnosed with cardiogenic shock, irrespective of underlying etiology or therapeutic strategy. The registry includes a wide range of cardiogenic shock etiologies, including: * Myocardial infarction (MI) * Fulminant myocarditis * Acute decompensated heart failure * Severe valvular disease * Post-cardiotomy or perioperative cardiogenic shock
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* Patients admitted with cardiogenic shock to the University hospital Basel (diagnosis at the time of admission) or development of cardiogenic shock during the hospital stay * Age ≥18 years * Provision of written ICF * Clinical diagnosis of cardiogenic shock. * impaired organ perfusion due to primary cardiac dysfunction, * persistent systolic blood pressure (SBP) \<90 mmHg for ≥30 minutes, or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain adequate perfusion and * evidence of systemic hypoperfusion with arterial lactate ≥2 mmol/L or venous lactate ≥3 mmol/l and ≥1 of the following: * Cold or clammy extremities * Altered mental status * Reduced urine output * Signs of volume overload or congestion (on clinical exam, imaging, or invasive monitoring) * Patients with normotensive cardiogenic shock (SBP ≥90 mmHg without vasopressors or MCS) may also be included if clear signs of hypoperfusion (arterial lactate ≥2 mmol/L or venous lactate ≥3 mmol/l) and cardiac dysfunction are present and alternative causes are excluded Exclusion criteria: * Age \<18 years * Refusal to provide informed consent by the patient or their legally authorized representative
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute decompensated heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Hospital Basel
RECRUITINGBasel, Canton of Basel-City, 4031, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Every minute counts: study tracks how delays shape heart attack survival
- The heart rhythm threat hiding in heart attack wards
- Stick-On patch aims to catch dangerous heart decline sooner
- Heart pump timing put to the test in deadly heart attack shock
- AI on your phone: the future of heart attack detection in the field?
- A second chance for the heart: can rehab rewrite the story after shock?